Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 2004

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Increased titer of anti-beta 2-glycoprotein I IgG antibody among factor V

Leiden carriers during oral contraceptive use.

AUTHORS

Póka R; Vad S; Lakos G; Bereczki Z; Kiss E

SOURCE

Contraception. 2004 Jan;69(1):27-30.

ABSTRACT

The risk of thromboembolism during oral contraceptive (OC) use is increased among factor V Leiden (FVL) carriers

compared to women with wild-type genotype of the gene for coagulation factor V (FV). The carrier frequency in the

general population is too high for FVL alone to be responsible for the reported association. Additional risk factors

may be required to explain the increased risk of thromboembolism of carriers during OC use. We conducted a case-

control study to compare the titer of anti-ß2-glycoprotein I immunoglobulin G (IgG) and the frequency of elevated titer

of IgG type anti-ß2-glycoprotein I antibody between FVL carriers and individuals with FV wild-type genotype with and

without pill use. An asymptomatic population of 313 unrelated nonpregnant women were screened for FVL and for the

presence of anti-ß2-glycoprotein I IgG antibody. Sixty-six women were FVL carriers and 247 had normal genotype.

One-hundred and thirty-five women used OC at the time of screening and 178 did not. Among FVL carriers, OC pill

users had a higher mean anti-ß2-glycoprotein I IgG titer than nonusers (9.2 SGU/mL vs. 4.7 SGU/mL, p = 0.0485).

Among women with FV wild-type genotype, there was no significant difference in anti-ß2-glycoprotein I IgG titers

between users and nonusers of OCs (6.4 SGU/mL and 6.0 SGU/mL, respectively; p = 0.7010). The odds of an

elevated anti-ß2-glycoprotein I IgG titer during OC use in FVL heterozygous women was 2.41 (95% confidence

interval: 0.79 -7.39) relative to users with-type genotype. FVL may contribute to the development of elevated titer of IgG

type anti-ß2-glycoprotein I antibody during OC use. The elevated titer of IgG type anti-ß2-glycoprotein I antibody may

select women among FVL carriers during OC use with an increased risk of thromboembolism. (PubHealth.info

Document ID: CONT1T 572-06)

PubHealth.info NOTE: The author(s) of this article titled, "Increased titer of anti-beta 2-glycoprotein I IgG antibody

among factor V Leiden carriers during oral contraceptive use.", is(are) Póka R; Vad S; Lakos G; Bereczki Z; Kiss

E. The source of this article is "Contraception. 2004 Jan;69(1):27-30.". This article was published in 2004 in English

language(s). (PubHealth.info® Document ID: CONT1T 572-06. All rights reserved with PubHealth.info) PIN: 572

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.